Ivan Kairatov is a leading biopharma expert with a deep specialization in the intersection of
The persistent challenge of hospital-acquired infections remains a critical hurdle for healthcare
The world of forensic pathology is undergoing a molecular revolution, moving beyond the physical observations of the past toward a data-driven future. Ivan Kairatov, a distinguished expert in biopharmaceutical innovation and research and development, stands at the forefront of this shift. With a
The traditional medical model has spent decades dissecting the mechanisms of failure, yet the most profound insights into human health may actually lie in the study of those who thrive against the odds. Longevity genomics represents a fundamental shift in the landscape of precision medicine, moving
Matthias Aizenberg and Ivan Kairatov discuss the shifting landscape of American mental health,
A diagnosis of advanced, metastatic breast cancer has long been viewed as a grim final chapter, but
The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the…
The End of the Old Biopharma Playbook The biopharmaceutical industry is confronting a structural
By 2030, the tissue-engineering market is projected to exceed $32.45 billion , reflecting a
The landscape of rare disease drug development is littered with clinical failures. For every
Major policy changes are colliding with the complex economics of drug development. For B2B
The High Stakes of the Alzheimer’s Waiting Game A diagnosis of Alzheimer’s Disease often feels like being handed a map with the ink still wet, leaving families to navigate a landscape where the landmarks of memory and independence could vanish tomorrow or remain for a decade. This profound
Scientists have successfully mapped the internal genetic blueprints of millions of individual
The integration of sophisticated computational algorithms into the oral healthcare sector has
